Drugs / HLX22
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03916094 | Jul 2019 → Jan 2021 | cancer | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07176702 | Sep 2025 → Mar 2027 expected | pancreatic ductal adenocarcinoma | Shanghai Zhongshan Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06832202 | Apr 2025 → Jun 2027 expected | hormone receptor-positive breast cancer | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT04908813 | Sep 2021 → Dec 2024 | gastric cancer | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07294508 | Feb 2026 → Jan 2028 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07294534 | Jan 2026 → Sep 2028 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06532006 | Nov 2024 → Jun 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX22 | “HLX22 is a novel monoclonal antibody targeting HER2” NCT07294534 ↗ |
| Action | Inhibit | “a novel anti-HER2 antibody” PMID 38986608 ↗ Jul 2024 |
| Modality | Monoclonal antibody | “HLX22 is a novel monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2).” PMID 37140695 ↗ May 2023 |
| Route | Intravenous | “received intravenous HLX22 once every 3 weeks” PMID 37140695 ↗ May 2023 |
| Target | ERBB2 | “HLX22 is a novel monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2).” PMID 37140695 ↗ May 2023 |